Anil K Sood

List of Publications by Year
in descending order

337 papers	35,637 citations	4960 84 h-index	3915 177 g-index
391 all docs	391 docs citations	391 times ranked	56509 citing authors

#	Article	IF	Citations
1	Gene Body Methylation of the Lymphocyte-Specific GeneCARD11Results in Its Overexpression and Regulates Cancer mTOR Signaling. Molecular Cancer Research, 2022, 19, 1917-1928.	3.4	3
2	Podoplanin promotes tumor growth, platelet aggregation, and venous thrombosis in murine models of ovarian cancer. Journal of Thrombosis and Haemostasis, 2022, 20, 104-114.	3.8	23
3	The life cycle of polyploid giant cancer cells and dormancy in cancer: Opportunities for novel therapeutic interventions. Seminars in Cancer Biology, 2022, 81, 132-144.	9.6	23
4	Of vascular defense, hemostasis, cancer, and platelet biology: an evolutionary perspective. Cancer and Metastasis Reviews, 2022, 41, 147-172.	5.9	6
5	Targeting CCR2+ macrophages with BET inhibitor overcomes adaptive resistance to anti-VEGF therapy in ovarian cancer. Journal of Cancer Research and Clinical Oncology, 2022, 148, 803.	2.5	5
6	Endothelial p130cas confers resistance to anti-angiogenesis therapy. Cell Reports, 2022, 38, 110301.	6.4	4
7	Race-associated Molecular Changes in Gynecologic Malignancies. Cancer Research Communications, 2022, 2, 99-109.	1.7	6
8	Spatially resolved transcriptomics of high-grade serous ovarian carcinoma. IScience, 2022, 25, 103923.	4.1	23
9	Molecular Correlates of Venous Thromboembolism (VTE) in Ovarian Cancer. Cancers, 2022, 14, 1496.	3.7	6
10	Clinical analysis of pathologic complete responders in advanced-stage ovarian cancer. Gynecologic Oncology, 2022, 165, 82-89.	1.4	2
11	Novel markers for liquid biopsies in cancer management: Circulating platelets and extracellular vesicles. Molecular Cancer Therapeutics, 2022, , .	4.1	5
12	Platelets Increase the Expression of PD-L1 in Ovarian Cancer. Cancers, 2022, 14, 2498.	3.7	12
13	The hidden role of paxillin: localization to nucleus promotes tumor angiogenesis. Oncogene, 2021, 40, 384-395.	5.9	17
14	Oncolytic HSV Therapy Modulates Vesicular Trafficking Inducing Cisplatin Sensitivity and Antitumor Immunity. Clinical Cancer Research, 2021, 27, 542-553.	7.0	14
15	Uterine carcinosarcoma: Contemporary clinical summary, molecular updates, and future research opportunity. Gynecologic Oncology, 2021, 160, 586-601.	1.4	56
16	Possible candidate population for neoadjuvant chemotherapy in women with advanced ovarian cancer. Gynecologic Oncology, 2021, 160, 32-39.	1.4	20
17	Assessment of In Vivo siRNA Delivery in Mouse Models. Methods in Molecular Biology, 2021, 2372, 157-168.	0.9	1
18	The clinical efficacy and safety of single-agent pembrolizumab in patients with recurrent granulosa cell tumors of the ovary: a case series from a phase II basket trial. Investigational New Drugs, 2021, 39, 829-835.	2.6	8

#	Article	IF	Citations
19	Gain-of-function p53 protein transferred via small extracellular vesicles promotes conversion of fibroblasts to a cancer-associated phenotype. Cell Reports, 2021, 34, 108726.	6.4	27
20	Distinct TÂcell receptor repertoire diversity of clinically defined high-grade serous ovarian cancer treatment subgroups. IScience, 2021, 24, 102053.	4.1	6
21	Emerging Trends in Neoadjuvant Chemotherapy for Ovarian Cancer. Cancers, 2021, 13, 626.	3.7	26
22	PRKAR1B-AS2 Long Noncoding RNA Promotes Tumorigenesis, Survival, and Chemoresistance via the PI3K/AKT/mTOR Pathway. International Journal of Molecular Sciences, 2021, 22, 1882.	4.1	13
23	A Modified 2 Tier Chemotherapy Response Score (CRS) and Other Histopathologic Features for Predicting Outcomes of Patients with Advanced Extrauterine High-Grade Serous Carcinoma after Neoadjuvant Chemotherapy. Cancers, 2021, 13, 704.	3.7	3
24	Clinical significance of homologous recombination deficiency score testing in endometrial Cancer. Gynecologic Oncology, 2021, 160, 777-785.	1.4	21
25	Ferroptosis as a mechanism to mediate p53 function in tumor radiosensitivity. Oncogene, 2021, 40, 3533-3547.	5.9	101
26	The effect of platelet G proteins on platelet extravasation and tumor growth in the murine model of ovarian cancer. Blood Advances, 2021, 5, 1947-1951.	5.2	10
27	Dasatinib, paclitaxel, and carboplatin in women with advanced-stage or recurrent endometrial cancer: A pilot clinical and translational study. Gynecologic Oncology, 2021, 161, 104-112.	1.4	4
28	Chronic difficulties are associated with poorer psychosocial functioning in the first year postâ€diagnosis in epithelial ovarian cancer patients. Psycho-Oncology, 2021, 30, 954-961.	2.3	4
29	Cost-effectiveness of laparoscopic disease assessment in patients with newly diagnosed advanced ovarian cancer. Gynecologic Oncology, 2021, 161, 56-62.	1.4	7
30	CD8+ T cells inhibit metastasis and CXCL4 regulates its function. British Journal of Cancer, 2021, 125, 176-189.	6.4	21
31	Combined VEGFR and MAPK pathway inhibition in angiosarcoma. Scientific Reports, 2021, 11, 9362.	3.3	14
32	Positive Psychosocial Factors and Oxytocin in the Ovarian Tumor Microenvironment. Psychosomatic Medicine, 2021, 83, 417-422.	2.0	4
33	Inactivating Mutations of the IK Gene Weaken Ku80/Ku70-Mediated DNA Repair and Sensitize Endometrial Cancer to Chemotherapy. Cancers, 2021, 13, 2487.	3.7	0
34	Joint IARC/NCI International Cancer Seminar Series Report: expert consensus on future directions for ovarian carcinoma research. Carcinogenesis, 2021, 42, 785-793.	2.8	6
35	Extensive three-dimensional intratumor proteomic heterogeneity revealed by multiregion sampling in high-grade serous ovarian tumor specimens. IScience, 2021, 24, 102757.	4.1	20
36	Mitochondria in epithelial ovarian carcinoma exhibit abnormal phenotypes and blunted associations with biobehavioral factors. Scientific Reports, 2021, 11, 11595.	3.3	13

#	Article	IF	Citations
37	Timing of surgery in patients with partial response or stable disease after neoadjuvant chemotherapy for advanced ovarian cancer. Gynecologic Oncology, 2021, 161, 660-667.	1.4	6
38	Human tumor microenvironment chip evaluates the consequences of platelet extravasation and combinatorial antitumor-antiplatelet therapy in ovarian cancer. Science Advances, 2021, 7, .	10.3	43
39	Expression of B7â€“H4 and IDO1 is associated with drug resistance and poor prognosis in high-grade serous ovarian carcinomas. Human Pathology, 2021, 113, 20-27.	2.0	13
40	The Provocative Roles of Platelets in Liver Disease and Cancer. Frontiers in Oncology, 2021, 11, 643815.	2.8	10
41	Factors associated with response to neoadjuvant chemotherapy in advanced stage ovarian cancer. Gynecologic Oncology, 2021, 162, 65-71.	1.4	3
42	MEK inhibition overcomes resistance to EphA2-targeted therapy in uterine cancer. Gynecologic Oncology, 2021, 163, 181-190.	1.4	5
43	Rural residence is related to shorter survival in epithelial ovarian cancer patients. Gynecologic Oncology, 2021, 163, 22-28.	1.4	16
44	CD63-mediated cloaking of VEGF in small extracellular vesicles contributes to anti-VEGF therapy resistance. Cell Reports, 2021, 36, 109549.	6.4	20
45	Rationale for combination PARP inhibitor and antiangiogenic treatment in advanced epithelial ovarian cancer: A review. Gynecologic Oncology, 2021, 162, 482-495.	1.4	31
46	Clinically translatable quantitative molecular photoacoustic imaging with liposome-encapsulated ICG J-aggregates. Nature Communications, 2021, 12, 5410.	12.8	60
47	IL-6 promotes drug resistance through formation of polyploid giant cancer cells and stromal fibroblast reprogramming. Oncogenesis, 2021, 10, 65.	4.9	30
48	Immune microenvironment composition in high-grade serous ovarian cancers based on BRCA mutational status. Journal of Cancer Research and Clinical Oncology, 2021, 147, 3545-3555.	2.5	5
49	Antihypertensive medication use and ovarian cancer survival. Gynecologic Oncology, 2021, 163, 342-347.	1.4	4
50	Phase Ib Dose Expansion and Translational Analyses of Olaparib in Combination with Capivasertib in Recurrent Endometrial, Triple-Negative Breast, and Ovarian Cancer. Clinical Cancer Research, 2021, 27, 6354-6365.	7.0	31
51	Rational Combination of CRM1 Inhibitor Selinexor and Olaparib Shows Synergy in Ovarian Cancer Cell Lines and Mouse Models. Molecular Cancer Therapeutics, 2021, 20, 2352-2361.	4.1	5
52	Attributions of survival and methods of coping of long-term ovarian cancer survivors: a qualitative study. BMC Women's Health, 2021, 21, 376.	2.0	1
53	RNA-binding protein FXR1 drives cMYC translation by recruiting eIF4F complex to the translation start site. Cell Reports, 2021, 37, 109934.	6.4	34
54	Pathologic distribution at the time of interval tumor reductive surgery informs personalized surgery for high-grade ovarian cancer. International Journal of Gynecological Cancer, 2021, 31, 232-237.	2.5	0

#	Article	IF	Citations
55	Correlation of surgeon radiology assessment with laparoscopic disease site scoring in patients with advanced ovarian cancer. International Journal of Gynecological Cancer, 2021, 31, 92-97.	2.5	3
56	Clinical and biological significance of EZH2 expression in endometrial cancer. Cancer Biology and Therapy, 2020, 21, 147-156.	3.4	21
57	Placenta-derived extracellular vesicles induce preeclampsia in mouse models. Haematologica, 2020, 105, 1686-1694.	3.5	65
58	GATA3 as a master regulator for interactions of tumor-associated macrophages with high-grade serous ovarian carcinoma. Cellular Signalling, 2020, 68, 109539.	3.6	81
59	Can stress promote the pathophysiology of brain metastases? A critical review of biobehavioral mechanisms. Brain, Behavior, and Immunity, 2020, 87, 860-880.	4.1	4
60	Panâ€cancer clinical and molecular analysis of racial disparities. Cancer, 2020, 126, 800-807.	4.1	25
61	A Solution to the Dilution: The Role for Biomarkers in Advanced Ovarian Cancer. Clinical Cancer Research, 2020, 26, 9-10.	7.0	1
62	Predictors of survival trajectories among women with epithelial ovarian cancer. Gynecologic Oncology, 2020, 156, 459-466.	1.4	26
63	Long non-coding RNAs in ovarian cancer: expression profile and functional spectrum. RNA Biology, 2020, 17, 1523-1534.	3.1	22
64	Sustained Adrenergic Activation of YAP1 Induces Anoikis Resistance in Cervical Cancer Cells. IScience, 2020, 23, 101289.	4.1	9
65	Epithelialâ€mesenchymal transition polarization in ovarian carcinomas from patients with high social isolation. Cancer, 2020, 126, 4407-4413.	4.1	15
66	Characterization of and isolation methods for plant leaf nanovesicles and small extracellular vesicles. Nanomedicine: Nanotechnology, Biology, and Medicine, 2020, 29, 102271.	3.3	41
67	The role of neoadjuvant chemotherapy in the management of low-grade serous carcinoma of the ovary and peritoneum: Further evidence of relative chemoresistance. Gynecologic Oncology, 2020, 158, 653-658.	1.4	29
68	Targeting progesterone signaling prevents metastatic ovarian cancer. Proceedings of the National Academy of Sciences of the United States of America, 2020, 117, 31993-32004.	7.1	29
69	OvCa-Chip microsystem recreates vascular endotheliumâ€“mediated platelet extravasation in ovarian cancer. Blood Advances, 2020, 4, 3329-3342.	5.2	33
70	Blockade of the Short Form of Prolactin Receptor Induces FOXO3a/EIF-4EBP1â€“Mediated Cell Death in Uterine Cancer. Molecular Cancer Therapeutics, 2020, 19, 1943-1954.	4.1	5
71	Enhanced Immunotherapy with LHRH-R Targeted Lytic Peptide in Ovarian Cancer. Molecular Cancer Therapeutics, 2020, 19, 2396-2406.	4.1	7
72	Minimally invasive surgery for early-stage ovarian cancer: Association between hospital surgical volume and short-term perioperative outcomes. Gynecologic Oncology, 2020, 158, 59-65.	1.4	12

#	Article	IF	Citations
73	Role of Micro-RNA for Pain After Surgery. Anesthesia and Analgesia, 2020, 130, 1638-1652.	2.2	9
74	Molecular Pathways and Targeted Therapies for Malignant Ovarian Germ Cell Tumors and Sex Cordâ€“Stromal Tumors: A Contemporary Review. Cancers, 2020, 12, 1398.	3.7	24
75	NRG1/ERBB3 Pathway Activation Induces Acquired Resistance to XPO1 Inhibitors. Molecular Cancer Therapeutics, 2020, 19, 1727-1735.	4.1	5
76	Minimally Invasive Surgery and Risk of Capsule Rupture for Women With Early-Stage Ovarian Cancer. JAMA Oncology, 2020, 6, 1110.	7.1	37
77	Pelvic fractures and changes in bone mineral density after radiotherapy for cervical, endometrial, and vaginal cancer: A prospective study of 239 women. Cancer, 2020, 126, 2607-2613.	4.1	20
78	Induction of antitumor immunity in mice by the combination of nanoparticle-based photothermolysis and anti-PD-1 checkpoint inhibition. Nanomedicine: Nanotechnology, Biology, and Medicine, 2020, 25, 102169.	3.3	21
79	Targeting Forward and Reverse EphB4/EFNB2 Signaling by a Peptide with Dual Functions. Scientific Reports, 2020, 10, 520.	3.3	9
80	Demcizumab combined with paclitaxel for platinum-resistant ovarian, primary peritoneal, and fallopian tube cancer: The SIERRA open-label phase Ib trial. Gynecologic Oncology, 2020, 157, 386-391.	1.4	25
81	Evolving population-based statistics for rare epithelial ovarian cancers. Gynecologic Oncology, 2020, 157, 3-11.	1.4	13
82	Diagnosis-shift between low-grade serous ovarian cancer and serous borderline ovarian tumor: A population-based study. Gynecologic Oncology, 2020, 157, 21-28.	1.4	8
83	Low-grade serous ovarian cancer: State of the science. Gynecologic Oncology, 2020, 156, 715-725.	1.4	74
84	Significance of lymph node ratio on survival of women with borderline ovarian tumors. Archives of Gynecology and Obstetrics, 2020, 301, 1289-1298.	1.7	8
85	Molecular Analysis of Clinically Defined Subsets of High-Grade Serous Ovarian Cancer. Cell Reports, 2020, 31, 107502.	6.4	69
86	Therapeutic efficacy of liposomal Grb2 antisense oligodeoxynucleotide (L-Grb2) in preclinical models of ovarian and uterine cancer. Oncotarget, 2020, 11, 2819-2833.	1.8	4
87	Prospective Validation of an Ex Vivo, Patient-Derived 3D Spheroid Model for Response Predictions in Newly Diagnosed Ovarian Cancer. Scientific Reports, 2019, 9, 11153.	3.3	44
88	Identifying and targeting angiogenesis-related microRNAs in ovarian cancer. Oncogene, 2019, 38, 6095-6108.	5.9	40
89	Chromosomal Instability in Tumor Initiation and Development. Cancer Research, 2019, 79, 3995-4002.	0.9	67
90	Prospective pilot trial with combination of propranolol with chemotherapy in patients with epithelial ovarian cancer and evaluation on circulating immune cell gene expression. Gynecologic Oncology, 2019, 154, 524-530.	1.4	24

#	Article	IF	Citations
91	Copper-64 Labeled PEGylated Exosomes for In Vivo Positron Emission Tomography and Enhanced Tumor Retention. Bioconjugate Chemistry, 2019, 30, 2675-2683.	3.6	66
92	PTGER3 induces ovary tumorigenesis and confers resistance to cisplatin therapy through up-regulation Ras-MAPK/Erk-ETS1-ELK1/CFTR1 axis. EBioMedicine, 2019, 40, 290-304.	6.1	36
93	Adaptive responses in a PARP inhibitor window of opportunity trial illustrate limited functional interlesional heterogeneity and potential combination therapy options. Oncotarget, 2019, 10, 3533-3546.	1.8	19
94	Activating p53 family member TAp63: A novel therapeutic strategy for targeting p53â€altered tumors. Cancer, 2019, 125, 2409-2422.	4.1	15
95	Pan-cancer genomic analysis links 3â€™UTR DNA methylation with increased gene expression in T cells. EBioMedicine, 2019, 43, 127-137.	6.1	48
96	Quaking orchestrates a post-transcriptional regulatory network of endothelial cell cycle progression critical to angiogenesis and metastasis. Oncogene, 2019, 38, 5191-5210.	5.9	19
97	Circular RNAs in Cancer. Molecular Therapy - Nucleic Acids, 2019, 16, 118-129.	5.1	325
98	GnRH-Râ€“Targeted Lytic Peptide SensitizesBRCAWild-type Ovarian Cancer to PARP Inhibition. Molecular Cancer Therapeutics, 2019, 18, 969-979.	4.1	12
99	exRNA Atlas Analysis Reveals Distinct Extracellular RNA Cargo Types and Their Carriers Present across Human Biofluids. Cell, 2019, 177, 463-477.e15.	28.9	228
100	Small RNA Sequencing across Diverse Biofluids Identifies Optimal Methods for exRNA Isolation. Cell, 2019, 177, 446-462.e16.	28.9	214
101	Oxytocin in the tumor microenvironment is associated with lower inflammation and longer survival in advanced epithelial ovarian cancer patients. Psychoneuroendocrinology, 2019, 106, 244-251.	2.7	14
102	Performance of the MasSpec Pen for Rapid Diagnosis of Ovarian Cancer. Clinical Chemistry, 2019, 65, 674-683.	3.2	77
103	Mucinous borderline ovarian tumor versus invasive well-differentiated mucinous ovarian cancer: Difference in characteristics and outcomes. Gynecologic Oncology, 2019, 153, 230-237.	1.4	16
104	6-Phosphofructo-2-Kinase/Fructose-2,6-Biphosphatase-2 Regulates TP53-Dependent Paclitaxel Sensitivity in Ovarian and Breast Cancers. Clinical Cancer Research, 2019, 25, 5702-5716.	7.0	22
105	Mechanisms of nuclear content loading to exosomes. Science Advances, 2019, 5, eaax8849.	10.3	176
106	miRNA551b-3p Activates an Oncostatin Signaling Module for the Progression of Triple-Negative Breast Cancer. Cell Reports, 2019, 29, 4389-4406.e10.	6.4	55
107	Tumor core biopsies adequately represent immune microenvironment of high-grade serous carcinoma. Scientific Reports, 2019, 9, 17589.	3.3	12
108	Pharmacogenomic analysis of patient-derived tumor cells in gynecologic cancers. Genome Biology, 2019, 20, 253.	8.8	16

#	Article	IF	Citations
109	Exploring and comparing adverse events between PARP inhibitors. Lancet Oncology, The, 2019, 20, e15-e28.	10.7	287
110	Ovarian cancer cell-derived lysophosphatidic acid induces glycolytic shift and cancer-associated fibroblast-phenotype in normal and peritumoral fibroblasts. Cancer Letters, 2019, 442, 464-474.	7.2	70
111	EGFL6 promotes breast cancer by simultaneously enhancing cancer cell metastasis and stimulating tumor angiogenesis. Oncogene, 2019, 38, 2123-2134.	5.9	27
112	Perineural invasion (PNI) in vulvar carcinoma: A review of 421 cases. Gynecologic Oncology, 2019, 152, 101-105.	1.4	18
113	Predicting Novel Therapies and Targets: Regulation of Notch3 by the Bromodomain Protein BRD4. Molecular Cancer Therapeutics, 2019, 18, 421-436.	4.1	10
114	PRKRA/PACT Expression Promotes Chemoresistance of Mucinous Ovarian Cancer. Molecular Cancer Therapeutics, 2019, 18, 162-172.	4.1	23
115	ZRANB1 Is an EZH2 Deubiquitinase and a Potential Therapeutic Target in Breast Cancer. Cell Reports, 2018, 23, 823-837.	6.4	42
116	Sustained Adrenergic Signaling Promotes Intratumoral Innervation through BDNF Induction. Cancer Research, 2018, 78, 3233-3242.	0.9	69
117	Pan-Cancer Analysis of lncRNA Regulation Supports Their Targeting of Cancer Genes in Each Tumor Context. Cell Reports, 2018, 23, 297-312.e12.	6.4	205
118	The Platelet Lifeline to Cancer: Challenges and Opportunities. Cancer Cell, 2018, 33, 965-983.	16.8	390
119	Tuning microtubule dynamics to enhance cancer therapy by modulating FER-mediated CRMP2 phosphorylation. Nature Communications, 2018, 9, 476.	12.8	44
120	A-to-I miR-378a-3p editing can prevent melanoma progression via regulation of PARVA expression. Nature Communications, 2018, 9, 461.	12.8	61
121	LPA Induces Metabolic Reprogramming in Ovarian Cancer via a Pseudohypoxic Response. Cancer Research, 2018, 78, 1923-1934.	0.9	61
122	Isolation of Extracellular RNA from Serum/Plasma. Methods in Molecular Biology, 2018, 1740, 43-57.	0.9	11
123	HN1L Promotes Triple-Negative Breast Cancer Stem Cells through LEPR-STAT3 Pathway. Stem Cell Reports, 2018, 10, 212-227.	4.8	42
124	Association of biobehavioral factors with non-coding RNAs in cervical cancer. BioScience Trends, 2018, 12, 24-31.	3.4	3
125	A Comprehensive Pan-Cancer Molecular Study of Gynecologic and Breast Cancers. Cancer Cell, 2018, 33, 690-705.e9.	16.8	478
126	The role of long noncoding RNAs in cancer: the dark matter matters. Current Opinion in Genetics and Development, 2018, 48, 8-15.	3.3	122

#	Article	IF	Citations
127	MYC Targeted Long Noncoding RNA DANCR Promotes Cancer in Part by Reducing p21 Levels. Cancer Research, 2018, 78, 64-74.	0.9	87
128	Peroxisomes contribute to oxidative stress in neurons during doxorubicin-based chemotherapy. Molecular and Cellular Neurosciences, 2018, 86, 65-71.	2.2	35
129	Inhibiting Nuclear Phospho-Progesterone Receptor Enhances Antitumor Activity of Onapristone in Uterine Cancer. Molecular Cancer Therapeutics, 2018, 17, 464-473.	4.1	4
130	RNA interference-based therapy and its delivery systems. Cancer and Metastasis Reviews, 2018, 37, 107-124.	5.9	201
131	Biobehavioral modulation of the exosome transcriptome in ovarian carcinoma. Cancer, 2018, 124, 580-586.	4.1	27
132	Aspirin use and endometrial cancer risk and survival. Gynecologic Oncology, 2018, 148, 222-232.	1.4	34
133	Exosomal miRNA confers chemo resistance via targeting Cav1/p-gp/M2-type macrophage axis in ovarian cancer. EBioMedicine, 2018, 38, 100-112.	6.1	159
134	The role of tumor microenvironment in resistance to anti-angiogenic therapy. F1000Research, 2018, 7, 326.	1.6	47
135	Bone protection by inhibition of microRNA-182. Nature Communications, 2018, 9, 4108.	12.8	71
136	Integrated Analysis of Genetic Ancestry and Genomic Alterations across Cancers. Cancer Cell, 2018, 34, 549-560.e9.	16.8	168
137	Trends of low-grade serous ovarian carcinoma in the United States. Journal of Gynecologic Oncology, 2018, 29, e15.	2.2	29
138	Concordance of a laparoscopic scoring algorithm with primary surgery findings in advanced stage ovarian cancer. Gynecologic Oncology, 2018, 151, 428-432.	1.4	19
139	A practical guide for the safe implementation of early phase drug development and immunotherapy program in gynecologic oncology practice. Gynecologic Oncology, 2018, 151, 374-380.	1.4	1
140	Perioperative inhibition of Î²-adrenergic and COX2 signaling in a clinical trial in breast cancer patients improves tumor Ki-67 expression, serum cytokine levels, and PBMCs transcriptome. Brain, Behavior, and Immunity, 2018, 73, 294-309.	4.1	61
141	Defining Survivorship Trajectories Across Patients With Solid Tumors. JAMA Oncology, 2018, 4, 1519.	7.1	38
142	FABP4 as a key determinant of metastatic potential of ovarian cancer. Nature Communications, 2018, 9, 2923.	12.8	151
143	Ionizing Radiation Induces Endothelial Inflammation and Apoptosis via p90RSK-Mediated ERK5 S496 Phosphorylation. Frontiers in Cardiovascular Medicine, 2018, 5, 23.	2.4	17
144	Rucaparib in ovarian cancer: an update on safety, efficacy and place in therapy. Therapeutic Advances in Medical Oncology, 2018, 10, 175883591877848.	3.2	23

#	Article	IF	Citations
145	CD44-Targeting PLGA Nanoparticles Incorporating Paclitaxel and FAK siRNA Overcome Chemoresistance in Epithelial Ovarian Cancer. Cancer Research, 2018, 78, 6247-6256.	0.9	104
146	Bioactive lipid metabolism in platelet â€œfirst responderâ€•and cancer biology. Cancer and Metastasis Reviews, 2018, 37, 439-454.	5.9	14
147	Life stress as a risk factor for sustained anxiety and cortisol dysregulation during the first year of survivorship in ovarian cancer. Cancer, 2018, 124, 3401-3408.	4.1	23
148	Stress, inflammation, and eicosanoids: an emerging perspective. Cancer and Metastasis Reviews, 2018, 37, 203-211.	5.9	50
149	Selective delivery of PLXDC1 small interfering RNA to endothelial cells for anti-angiogenesis tumor therapy using CD44-targeted chitosan nanoparticles for epithelial ovarian cancer. Drug Delivery, 2018, 25, 1394-1402.	5.7	57
150	Adrenergic-mediated increases in INHBA drive CAF phenotype and collagens. JCI Insight, 2018, 3, .	5.0	5
151	ADH1B promotes mesothelial clearance and ovarian cancer infiltration. Oncotarget, 2018, 9, 25115-25126.	1.8	24
152	Calcium-mediated oxidative stress: a common mechanism in tight junction disruption by different types of cellular stress. Biochemical Journal, 2017, 474, 731-749.	3.7	63
153	Role of hysterectomy and lymphadenectomy in the management of early-stage borderline ovarian tumors. Gynecologic Oncology, 2017, 144, 496-502.	1.4	27
154	HSP70 Inhibition Synergistically Enhances the Effects of Magnetic Fluid Hyperthermia in Ovarian Cancer. Molecular Cancer Therapeutics, 2017, 16, 966-976.	4.1	47
155	Preclinical Mammalian Safety Studies of EPHARNA (DOPC Nanoliposomal EphA2-Targeted siRNA). Molecular Cancer Therapeutics, 2017, 16, 1114-1123.	4.1	94
156	Systematic characterization of A-to-I RNA editing hotspots in microRNAs across human cancers. Genome Research, 2017, 27, 1112-1125.	5.5	144
157	Metabolic Markers and Statistical Prediction of Serous Ovarian Cancer Aggressiveness by Ambient Ionization Mass Spectrometry Imaging. Cancer Research, 2017, 77, 2903-2913.	0.9	106
158	RNA nanoparticles harboring annexin A2 aptamer can target ovarian cancer for tumor-specific doxorubicin delivery. Nanomedicine: Nanotechnology, Biology, and Medicine, 2017, 13, 1183-1193.	3.3	60
159	Role of Platelet-Derived Tgfî²1 in the Progression of Ovarian Cancer. Clinical Cancer Research, 2017, 23, 5611-5621.	7.0	51
160	Quality of life among long-term survivors of advanced stage ovarian cancer: A cross-sectional approach. Gynecologic Oncology, 2017, 146, 101-108.	1.4	32
161	Endothelial cell malignancies: new insights from the laboratory and clinic. Npj Precision Oncology, 2017, 1, 11.	5.4	27
162	Role of YAP1 as a Marker of Sensitivity to Dual AKT and P70S6K Inhibition in Ovarian and Uterine Malignancies. Journal of the National Cancer Institute, 2017, 109, .	6.3	9

#	Article	IF	Citations
163	Delineation of retroperitoneal metastatic lymph nodes in ovarian cancer with near-infrared fluorescence imaging. Oncology Letters, 2017, 14, 2869-2877.	1.8	8
164	Macrophages Facilitate Resistance to Anti-VEGF Therapy by Altered VEGFR Expression. Clinical Cancer Research, 2017, 23, 7034-7046.	7.0	71
165	Immune cell profiling in cancer: molecular approaches to cell-specific identification. Npj Precision Oncology, 2017, 1, 26.	5.4	73
166	Platelets reduce anoikis and promote metastasis by activating YAP1 signaling. Nature Communications, 2017, 8, 310.	12.8	169
167	Platelet â€œfirst respondersâ€•in wound response, cancer, and metastasis. Cancer and Metastasis Reviews, 2017, 36, 199-213.	5.9	127
168	Diurnal cortisol rhythms, fatigue and psychosocial factors in five-year survivors of ovarian cancer. Psychoneuroendocrinology, 2017, 84, 139-142.	2.7	39
169	Phase II trial of bevacizumab with dose-dense paclitaxel as first-line treatment in patients with advanced ovarian cancer. Gynecologic Oncology, 2017, 147, 41-46.	1.4	17
170	Differential Effects of EGFL6 on Tumor versus Wound Angiogenesis. Cell Reports, 2017, 21, 2785-2795.	6.4	32
171	Stress hormones promote EGFR inhibitor resistance in NSCLC: Implications for combinations with Î²-blockers. Science Translational Medicine, 2017, 9, .	12.4	96
172	DNA methylation signatures and coagulation factors in the peripheral blood leucocytes of epithelial ovarian cancer. Carcinogenesis, 2017, 38, 797-805.	2.8	18
173	Therapeutic Targeting of AXL Receptor Tyrosine Kinase Inhibits Tumor Growth and Intraperitoneal Metastasis in Ovarian Cancer Models. Molecular Therapy - Nucleic Acids, 2017, 9, 251-262.	5.1	56
174	PRKCI promotes immune suppression in ovarian cancer. Genes and Development, 2017, 31, 1109-1121.	5.9	75
175	A small amount of cyclooxygenase 2 (COX2) is constitutively expressed in platelets. Platelets, 2017, 28, 99-102.	2.3	18
176	<scp>MIIP</scp> haploinsufficiency induces chromosomal instability and promotes tumour progression in colorectal cancer. Journal of Pathology, 2017, 241, 67-79.	4.5	13
177	Highly heterogeneous genomic landscape of uterine leiomyomas byÂwhole exome sequencing and genome-wide arrays. Fertility and Sterility, 2017, 107, 457-466.e9.	1.0	33
178	Macrophage depletion through colony stimulating factor 1 receptor pathway blockade overcomes adaptive resistance to anti-VEGF therapy. Oncotarget, 2017, 8, 96496-96505.	1.8	49
179	Cancer-associated fibroblasts regulate endothelial adhesion protein LPP to promote ovarian cancer chemoresistance. Journal of Clinical Investigation, 2017, 128, 589-606.	8.2	105
180	ADAMTS16 mutations sensitize ovarian cancer cells to platinum-based chemotherapy. Oncotarget, 2017, 8, 88410-88420.	1.8	10

#	Article	IF	Citations
181	Targeting the centriolar replication factor STIL synergizes with DNA damaging agents for treatment of ovarian cancer. Oncotarget, 2017, 8, 27380-27392.	1.8	13
182	Immunological consequences of ageing microvascular hemodynamic changes in view of cancer development and treatment. Oncotarget, 2017, 8, 69047-69061.	1.8	0
183	Role of Platelets in Adaptive Changes to Anti-Angiogenesis Therapy. Blood, 2017, 130, SCI-27-SCI-27.	1.4	0
184	Toll-like receptor 3-induced immune response by poly(D,L-lactide-co-glycolide) nanoparticles for dendritic cell-based cancer immunotherapy. International Journal of Nanomedicine, 2016, Volume 11, 5729-5742.	6.7	35
185	miR-509-3p is clinically significant and strongly attenuates cellular migration and multi-cellular spheroids in ovarian cancer. Oncotarget, 2016, 7, 25930-25948.	1.8	49
186	Hypertension, use of antihypertensive medications, and risk of epithelial ovarian cancer. International Journal of Cancer, 2016, 139, 291-299.	5.1	24
187	In vivo stepwise immunomodulation using chitosan nanoparticles as a platform nanotechnology for cancer immunotherapy. Scientific Reports, 2016, 6, 38348.	3.3	55
188	Differentiation therapy for hepatocellular carcinoma: Multifaceted effects of miRâ€148a on tumor growth and phenotype and liver fibrosis. Hepatology, 2016, 63, 864-879.	7.3	78
189	Platelets are not hyperreactive in patients with ovarian cancer. Platelets, 2016, 27, 716-718.	2.3	14
190	Immunological and pleiotropic effects of individual Î²-blockers and their relevance in cancer therapies. Expert Opinion on Investigational Drugs, 2016, 25, 501-505.	4.1	14
191	Yesâ€associated protein 1 and transcriptional coactivator with PDZâ€binding motif activate the mammalian target of rapamycin complex 1 pathway by regulating amino acid transporters in hepatocellular carcinoma. Hepatology, 2016, 63, 159-172.	7.3	115
192	Dll4 Inhibition plus Aflibercept Markedly Reduces Ovarian Tumor Growth. Molecular Cancer Therapeutics, 2016, 15, 1344-1352.	4.1	41
193	Evaluation of rucaparib and companion diagnostics in the PARP inhibitor landscape for recurrent ovarian cancer therapy. Future Oncology, 2016, 12, 1439-1456.	2.4	63
194	Direct Upregulation of STAT3 by MicroRNA-551b-3p Deregulates Growth and Metastasis of Ovarian Cancer. Cell Reports, 2016, 15, 1493-1504.	6.4	75
195	Characteristics of 10-year survivors of high-grade serous ovarian carcinoma. Gynecologic Oncology, 2016, 141, 260-263.	1.4	73
196	RNA-targeted therapeutics in cancer clinical trials: Current status and future directions. Cancer Treatment Reviews, 2016, 50, 35-47.	7.7	128
197	microRNA Therapeutics in Cancer â€" An Emerging Concept. EBioMedicine, 2016, 12, 34-42.	6.1	360
198	Evoking picomolar binding in RNA by a single phosphorodithioate linkage. Nucleic Acids Research, 2016, 44, 8052-8064.	14.5	94

#	Article	IF	Citations
199	Lipid profile of platelets and platelet-derived microparticles in ovarian cancer. BBA Clinical, 2016, 6, 76-81.	4.1	26
200	Salt-Inducible Kinase 2 Couples Ovarian Cancer Cell Metabolism with Survival at the Adipocyte-Rich Metastatic Niche. Cancer Cell, 2016, 30, 273-289.	16.8	143
201	Developing hyperpolarized silicon particles forin vivoMRI targeting of ovarian cancer. Journal of Medical Imaging, 2016, 3, 036001.	1.5	24
202	MIIP remodels Rac1-mediated cytoskeleton structure in suppression of endometrial cancer metastasis. Journal of Hematology and Oncology, 2016, 9, 112.	17.0	17
203	Association of Ovarian Tumor Î²2-Adrenergic Receptor Status with Ovarian Cancer Risk Factors and Survival. Cancer Epidemiology Biomarkers and Prevention, 2016, 25, 1587-1594.	2.5	22
204	Antitumor and Antiangiogenic Effects of Aspirin-PC in Ovarian Cancer. Molecular Cancer Therapeutics, 2016, 15, 2894-2904.	4.1	37
205	The rise of genomic profiling in ovarian cancer. Expert Review of Molecular Diagnostics, 2016, 16, 1337-1351.	3.1	18
206	Role of CTGF in Sensitivity to Hyperthermia in Ovarian and Uterine Cancers. Cell Reports, 2016, 17, 1621-1631.	6.4	21
207	Ovarian cancer. Nature Reviews Disease Primers, 2016, 2, 16061.	30.5	761
208	BET Inhibitors Suppress ALDH Activity by Targeting ALDH1A1 Super-Enhancer in Ovarian Cancer. Cancer Research, 2016, 76, 6320-6330.	0.9	115
209	A miR-192-EGR1-HOXB9 regulatory network controls the angiogenic switch in cancer. Nature Communications, 2016, 7, 11169.	12.8	100
210	Reply to beta blockers in epithelial ovarian cancer and beta-blockers and improved survival from ovarian cancer: New miracle treatment or another case of immortal person-time bias?. Cancer, 2016, 122, 325-326.	4.1	4
211	Thrombosis in Cancer: Research Priorities Identified by a National Cancer Institute/National Heart, Lung, and Blood Institute Strategic Working Group. Cancer Research, 2016, 76, 3671-3675.	0.9	27
212	Î”Np63/DGCR8-Dependent MicroRNAs Mediate Therapeutic Efficacy of HDAC Inhibitors in Cancer. Cancer Cell, 2016, 29, 874-888.	16.8	32
213	Precision Nanomedicine Using Dual PET and MR Temperature Imagingâ€“Guided Photothermal Therapy. Journal of Nuclear Medicine, 2016, 57, 1778-1783.	5.0	18
214	Role of Increased n-acetylaspartate Levels in Cancer. Journal of the National Cancer Institute, 2016, 108, djv426.	6.3	51
215	Prediction of anti-angiogenesis escape. Gynecologic Oncology, 2016, 141, 80-85.	1.4	15
216	Guidelines for the use and interpretation of assays for monitoring autophagy (3rd edition). Autophagy, 2016, 12, 1-222.	9.1	4,701

#	Article	IF	Citations
217	Assessment of In Vivo siRNA Delivery in Cancer Mouse Models. Methods in Molecular Biology, 2016, 1402, 189-197.	0.9	8
218	Copy number deletion of RAD50 as predictive marker of BRCAness and PARP inhibitor response in BRCA wild type ovarian cancer. Gynecologic Oncology, 2016, 141, 57-64.	1.4	33
219	miRNA Deregulation in Cancer Cells and the Tumor Microenvironment. Cancer Discovery, 2016, 6, 235-246.	9.4	554
220	Linalool-Incorporated Nanoparticles as a Novel Anticancer Agent for Epithelial Ovarian Carcinoma. Molecular Cancer Therapeutics, 2016, 15, 618-627.	4.1	27
221	Targeting the tumour microenvironment in ovarian cancer. European Journal of Cancer, 2016, 56, 131-143.	2.8	84
222	Complement Component 3 Is Regulated by TWIST1 and Mediates Epithelialâ€“Mesenchymal Transition. Journal of Immunology, 2016, 196, 1412-1418.	0.8	66
223	Adrenergic Stimulation of DUSP1 Impairs Chemotherapy Response in Ovarian Cancer. Clinical Cancer Research, 2016, 22, 1713-1724.	7.0	69
224	Profiling Long Noncoding RNA Expression Using Custom-Designed Microarray. Methods in Molecular Biology, 2016, 1402, 33-41.	0.9	6
225	FAK regulates platelet extravasation and tumor growth after antiangiogenic therapy withdrawal. Journal of Clinical Investigation, 2016, 126, 1885-1896.	8.2	101
226	TFEB ameliorates the impairment of the autophagy-lysosome pathway in neurons induced by doxorubicin. Aging, 2016, 8, 3507-3519.	3.1	47
227	Coevolution of neoplastic epithelial cells and multilineage stroma via polyploid giant cells during immortalization and transformation of mullerian epithelial cells. Genes and Cancer, 2016, 7, 60-72.	1.9	34
228	NO-dependent attenuation of TPA-induced immunoinflammatory skin changes in Balb/c mice by pindolol, heptaminol or ATRA, but not by verapamil. Oncotarget, 2016, 7, 47576-47585.	1.8	3
229	Therapeutic evaluation of microRNA-15a and microRNA-16 in ovarian cancer. Oncotarget, 2016, 7, 15093-15104.	1.8	61
230	Reciprocal positive selection for weakness - preventing olaparib resistance by inhibiting BRCA2. Oncotarget, 2016, 7, 20825-20839.	1.8	9
231	Continuous anti-angiogenic therapy after tumor progression in patients with recurrent high-grade epithelial ovarian cancer: phase I trial experience. Oncotarget, 2016, 7, 35132-35143.	1.8	9
232	Genome-wide perturbations by miRNAs map onto functional cellular pathways, identifying regulators of chromatin modifiers. Npj Systems Biology and Applications, 2015, 1, 15001.	3.0	3
233	Clinical impact of selective and nonselective betaâ€blockers on survival in patients with ovarian cancer. Cancer, 2015, 121, 3444-3451.	4.1	157
234	Eudaimonic wellâ€being and tumor norepinephrine in patients with epithelial ovarian cancer. Cancer, 2015, 121, 3543-3550.	4.1	15

#	Article	IF	Citations
235	Advances and Challenges of Liposome Assisted Drug Delivery. Frontiers in Pharmacology, 2015, 6, 286.	3.5	1,668
236	Tumor T1 Relaxation Time for Assessing Response to Bevacizumab Anti-Angiogenic Therapy in a Mouse Ovarian Cancer Model. PLoS ONE, 2015, 10, e0131095.	2.5	10
237	Significance of monocyte counts on tumor characteristics and survival outcome of women with endometrial cancer. Gynecologic Oncology, 2015, 138, 332-338.	1.4	35
238	Augmentation of Response to Chemotherapy by microRNA-506 Through Regulation of RAD51 in Serous Ovarian Cancers. Journal of the National Cancer Institute, 2015, 107, .	6.3	102
239	Electron cryotomography reveals ultrastructure alterations in platelets from patients with ovarian cancer. Proceedings of the National Academy of Sciences of the United States of America, 2015, 112, 14266-14271.	7.1	61
240	Long Noncoding RNA Ceruloplasmin Promotes Cancer Growth by Altering Glycolysis. Cell Reports, 2015, 13, 2395-2402.	6.4	105
241	<scp>STAMP</scp>2 increases oxidative stress and is critical forÂprostate cancer. EMBO Molecular Medicine, 2015, 7, 315-331.	6.9	52
242	Preclinical and clinical development of siRNA-based therapeutics. Advanced Drug Delivery Reviews, 2015, 87, 108-119.	13.7	382
243	Differential Platelet Levels Affect Response to Taxane-Based Therapy in Ovarian Cancer. Clinical Cancer Research, 2015, 21, 602-610.	7.0	72
244	Survival outcome of stage I ovarian clear cell carcinoma with lympho-vascular space invasion. Gynecologic Oncology, 2015, 136, 198-204.	1.4	17
245	Reduced adenosine-to-inosine miR-455-5p editing promotes melanoma growth and metastasis. Nature Cell Biology, 2015, 17, 311-321.	10.3	205
246	Rac1/Pak1/p38/MMP-2 Axis Regulates Angiogenesis in Ovarian Cancer. Clinical Cancer Research, 2015, 21, 2127-2137.	7.0	60
247	A framework for a personalized surgical approach to ovarian cancer. Nature Reviews Clinical Oncology, 2015, 12, 239-245.	27.6	118
248	Targeting c-MYC in Platinum-Resistant Ovarian Cancer. Molecular Cancer Therapeutics, 2015, 14, 2260-2269.	4.1	100
249	Biobehavioral and neuroendocrine correlates of antioxidant enzyme activity in ovarian carcinoma. Brain, Behavior, and Immunity, 2015, 50, 58-62.	4.1	6
250	Nanotechnology: Future of Oncotherapy. Clinical Cancer Research, 2015, 21, 3121-3130.	7.0	74
251	Fundamental Principles of Cancer Biology: Does It Have Relevance to the Perioperative Period?. Current Anesthesiology Reports, 2015, 5, 250-256.	2.0	7
252	Association of Somatic Mutations ofADAMTSGenes With Chemotherapy Sensitivity and Survival in High-Grade Serous Ovarian Carcinoma. JAMA Oncology, 2015, 1, 486.	7.1	32

#	Article	IF	Citations
253	TP53 loss creates therapeutic vulnerability inÂcolorectal cancer. Nature, 2015, 520, 697-701.	27.8	192
254	XPO1/CRM1 Inhibition Causes Antitumor Effects by Mitochondrial Accumulation of eIF5A. Clinical Cancer Research, 2015, 21, 3286-3297.	7.0	37
255	PTEN Expression as a Predictor of Response to Focal Adhesion Kinase Inhibition in Uterine Cancer. Molecular Cancer Therapeutics, 2015, 14, 1466-1475.	4.1	20
256	Predictors of optimal cytoreduction in patients with newly diagnosed advanced-stage epithelial ovarian cancer: Time to incorporate laparoscopic assessment into the standard of care. Gynecologic Oncology, 2015, 137, 553-558.	1.4	69
257	Erythropoietin Stimulates Tumor Growth via EphB4. Cancer Cell, 2015, 28, 610-622.	16.8	94
258	Depression and risk of epithelial ovarian cancer: Results from two large prospective cohort studies. Gynecologic Oncology, 2015, 139, 481-486.	1.4	50
259	Comprehensive Genomic Characterization of Long Non-coding RNAs across Human Cancers. Cancer Cell, 2015, 28, 529-540.	16.8	601
260	Sympathetic nervous system regulation of the tumour microenvironment. Nature Reviews Cancer, 2015, 15, 563-572.	28.4	406
261	State of the science: Emerging therapeutic strategies for targeting angiogenesis in ovarian cancer. Gynecologic Oncology, 2015, 138, 223-226.	1.4	33
262	Venous thromboembolism, interleukin-6 and survival outcomes in patients with advanced ovarian clear cell carcinoma. European Journal of Cancer, 2015, 51, 1978-1988.	2.8	44
263	Dual Metronomic Chemotherapy with Nab-Paclitaxel and Topotecan Has Potent Antiangiogenic Activity in Ovarian Cancer. Molecular Cancer Therapeutics, 2015, 14, 2677-2686.	4.1	9
264	Immunotherapy Targeting Folate Receptor Induces Cell Death Associated with Autophagy in Ovarian Cancer. Clinical Cancer Research, 2015, 21, 448-459.	7.0	48
265	Molecular Pathways: Translational and Therapeutic Implications of the Notch Signaling Pathway in Cancer. Clinical Cancer Research, 2015, 21, 955-961.	7.0	140
266	CDK5 Regulates Paclitaxel Sensitivity in Ovarian Cancer Cells by Modulating AKT Activation, p21Cip1- and p27Kip1-Mediated G1 Cell Cycle Arrest and Apoptosis. PLoS ONE, 2015, 10, e0131833.	2.5	28
267	Adrenergic regulation of monocyte chemotactic protein 1 leads to enhanced macrophage recruitment and ovarian carcinoma growth. Oncotarget, 2015, 6, 4266-4273.	1.8	78
268	Platelet Function in Ovarian Cancer. Blood, 2015, 126, 4656-4656.	1.4	0
269	Focal adhesion kinase. Cancer Biology and Therapy, 2014, 15, 919-929.	3.4	42
270	RNAi Therapies: Drugging the Undruggable. Science Translational Medicine, 2014, 6, 240ps7.	12.4	215

#	Article	IF	Citations
271	miR-101 suppresses the epithelial-to-mesenchymal transition by targeting ZEB1 and ZEB2 in ovarian carcinoma. Oncology Reports, 2014, 31, 2021-2028.	2.6	75
272	The RNA-Binding Protein DDX1 Promotes Primary MicroRNA Maturation and Inhibits Ovarian Tumor Progression. Cell Reports, 2014, 8, 1447-1460.	6.4	86
273	Copy Number Gain of hsa-miR-569 at 3q26.2 Leads to Loss of TP53INP1 and Aggressiveness of Epithelial Cancers. Cancer Cell, 2014, 26, 863-879.	16.8	46
274	miR-205 acts as a tumour radiosensitizer by targeting ZEB1 and Ubc13. Nature Communications, 2014, 5, 5671.	12.8	148
275	Molecular Biomarkers of Residual Disease after Surgical Debulking of High-Grade Serous Ovarian Cancer. Clinical Cancer Research, 2014, 20, 3280-3288.	7.0	80
276	Kallikrein family proteases KLK6 and KLK7 are potential early detection and diagnostic biomarkers for serous and papillary serous ovarian cancer subtypes. Journal of Ovarian Research, 2014, 7, 109.	3.0	29
277	Biologic Effects of Platelet-Derived Growth Factor Receptor Î± Blockade in Uterine Cancer. Clinical Cancer Research, 2014, 20, 2740-2750.	7.0	14
278	Clodronate inhibits tumor angiogenesis in mouse models of ovarian cancer. Cancer Biology and Therapy, 2014, 15, 1061-1067.	3.4	34
279	Metronomic Docetaxel in PRINT Nanoparticles and EZH2 Silencing Have Synergistic Antitumor Effect in Ovarian Cancer. Molecular Cancer Therapeutics, 2014, 13, 1750-1757.	4.1	31
280	Perioperative beta-blocker use and survival in lung cancer patients. Journal of Clinical Anesthesia, 2014, 26, 106-117.	1.6	45
281	Estrogen receptor expression and increased risk of lymphovascular space invasion in high-grade serous ovarian carcinoma. Gynecologic Oncology, 2014, 133, 473-479.	1.4	53
282	Notch3 Pathway Alterations in Ovarian Cancer. Cancer Research, 2014, 74, 3282-3293.	0.9	59
283	Platelets and cancer: a casual or causal relationship: revisited. Cancer and Metastasis Reviews, 2014, 33, 231-269.	5.9	258
284	Liposomal siRNA nanocarriers for cancer therapy. Advanced Drug Delivery Reviews, 2014, 66, 110-116.	13.7	364
285	Clinical Significance of CTNNB1 Mutation and Wnt Pathway Activation in Endometrioid Endometrial Carcinoma. Journal of the National Cancer Institute, 2014, 106, .	6.3	182
286	Hypoxia-mediated downregulation of miRNA biogenesis promotes tumour progression. Nature Communications, 2014, 5, 5202.	12.8	151
287	Hypoxia promotes stem cell phenotypes and poor prognosis through epigenetic regulation of DICER. Nature Communications, 2014, 5, 5203.	12.8	195
288	2â€²-OMe-phosphorodithioate-modified siRNAs show increased loading into the RISC complex and enhanced anti-tumour activity. Nature Communications, 2014, 5, 3459.	12.8	103

#	Article	IF	Citations
289	Calcium-dependent FAK/CREB/TNNC1 signalling mediates the effect of stromal MFAP5 on ovarian cancer metastatic potential. Nature Communications, 2014, 5, 5092.	12.8	112
290	Therapeutic Silencing of KRAS Using Systemically Delivered siRNAs. Molecular Cancer Therapeutics, 2014, 13, 2876-2885.	4.1	77
291	Bisphosphonates Inhibit Stellate Cell Activity and Enhance Antitumor Effects of Nanoparticle Albuminâ€“Bound Paclitaxel in Pancreatic Ductal Adenocarcinoma. Molecular Cancer Therapeutics, 2014, 13, 2583-2594.	4.1	24
292	Hematogenous Metastasis of Ovarian Cancer: Rethinking Mode of Spread. Cancer Cell, 2014, 26, 77-91.	16.8	252
293	Convergence of Nanotechnology and Cancer Prevention: Are We There Yet?. Cancer Prevention Research, 2014, 7, 973-992.	1.5	11
294	Geometrical confinement of Gd(DOTA) molecules within mesoporous silicon nanoconstructs for MR imaging of cancer. Cancer Letters, 2014, 352, 97-101.	7.2	31
295	Definition of PKC-Î±, CDK6, and MET as Therapeutic Targets in Triple-Negative Breast Cancer. Cancer Research, 2014, 74, 4822-4835.	0.9	61
296	Autocrine Effects of Tumor-Derived Complement. Cell Reports, 2014, 6, 1085-1095.	6.4	164
297	Platelet Effects on Ovarian Cancer. Seminars in Oncology, 2014, 41, 378-384.	2.2	48
298	Antagonism of Tumoral Prolactin Receptor Promotes Autophagy-Related Cell Death. Cell Reports, 2014, 7, 488-500.	6.4	43
299	Platelet-derived growth factor receptor alpha (PDGFRÎ±) targeting and relevant biomarkers in ovarian carcinoma. Gynecologic Oncology, 2014, 132, 166-175.	1.4	31
300	BRCA2 inhibition enhances cisplatinâ€mediated alterations in tumor cell proliferation, metabolism, and metastasis. Molecular Oncology, 2014, 8, 1429-1440.	4.6	32
301	Activation of YAP1 is associated with poor prognosis and response to taxanes in ovarian cancer. Anticancer Research, 2014, 34, 811-817.	1.1	46
302	Therapeutic Synergy between microRNA and siRNA in Ovarian Cancer Treatment. Cancer Discovery, 2013, 3, 1302-1315.	9.4	140
303	Tumour angiogenesis regulation by the miR-200 family. Nature Communications, 2013, 4, 2427.	12.8	363
304	Integrated Analyses Identify a Master MicroRNA Regulatory Network for the Mesenchymal Subtype in Serous Ovarian Cancer. Cancer Cell, 2013, 23, 186-199.	16.8	340
305	Overexpression of enhancer of zeste homolog 2 (EZH2) and focal adhesion kinase (FAK) in high grade endometrial carcinoma. Gynecologic Oncology, 2013, 128, 344-348.	1.4	50
306	Paraneoplastic Thrombocytosis in Ovarian Cancer. New England Journal of Medicine, 2012, 366, 610-618.	27.0	651

#	Article	IF	Citations
307	Social Influences on Clinical Outcomes of Patients With Ovarian Cancer. Journal of Clinical Oncology, 2012, 30, 2885-2890.	1.6	142
308	Platelets increase the proliferation of ovarian cancer cells. Blood, 2012, 120, 4869-4872.	1.4	190
309	Guidelines for the use and interpretation of assays for monitoring autophagy. Autophagy, 2012, 8, 445-544.	9.1	3,122
310	Social isolation is associated with elevated tumor norepinephrine in ovarian carcinoma patients. Brain, Behavior, and Immunity, 2011, 25, 250-255.	4.1	159
311	Stress Influences on Anoikis. Cancer Prevention Research, 2011, 4, 481-485.	1.5	27
312	A Novel Platform for Detection of CK+ and CKâ^' CTCs. Cancer Discovery, 2011, 1, 580-586.	9.4	189
313	Regulation of Tumor Angiogenesis by EZH2. Cancer Cell, 2010, 18, 185-197.	16.8	346
314	Adrenergic modulation of focal adhesion kinase protects human ovarian cancer cells from anoikis. Journal of Clinical Investigation, 2010, 120, 1515-1523.	8.2	231
315	Targeted Gene Silencing Using RGD-Labeled Chitosan Nanoparticles. Clinical Cancer Research, 2010, 16, 3910-3922.	7.0	245
316	EphA2 Immunoconjugate as Molecularly Targeted Chemotherapy for Ovarian Carcinoma. Journal of the National Cancer Institute, 2009, 101, 1193-1205.	6.3	78
317	Dual targeting of EphA2 and FAK in ovarian carcinoma. Cancer Biology and Therapy, 2009, 8, 1027-1034.	3.4	54
318	Therapeutic Targeting of ATP7B in Ovarian Carcinoma. Clinical Cancer Research, 2009, 15, 3770-3780.	7.0	128
319	Patterns of metastasis in sex cord-stromal tumors of the ovary: Can routine staging lymphadenectomy be omitted?. Gynecologic Oncology, 2009, 113, 86-90.	1.4	153
320	Anti-angiogenesis therapy with bevacizumab for patients with ovarian granulosa cell tumors. Gynecologic Oncology, 2009, 114, 431-436.	1.4	82
321	Functional significance of VEGFRâ€2 on ovarian cancer cells. International Journal of Cancer, 2009, 124, 1045-1053.	5.1	124
322	Depression, social support, and beta-adrenergic transcription control in human ovarian cancer. Brain, Behavior, and Immunity, 2009, 23, 176-183.	4.1	145
323	Biobehavioral Influences on Matrix Metalloproteinase Expression in Ovarian Carcinoma. Clinical Cancer Research, 2008, 14, 6839-6846.	7.0	137
324	Chronic stress promotes tumor growth and angiogenesis in a mouse model of ovarian carcinoma. Nature Medicine, 2006, 12, 939-944.	30.7	1,029

#	Article	IF	Citations
325	Stress Hormoneâ€“Mediated Invasion of Ovarian Cancer Cells. Clinical Cancer Research, 2006, 12, 369-375.	7.0	432
326	Novel Modification of the Vertical Rectus Abdominis Myocutaneous Flap for Neovagina Creation. Obstetrics and Gynecology, 2005, 105, 514-518.	2.4	19
327	Psychosocial factors and interleukin-6 among women with advanced ovarian cancer. Cancer, 2005, 104, 305-313.	4.1	185
328	Social Support, Psychological Distress, and Natural Killer Cell Activity in Ovarian Cancer. Journal of Clinical Oncology, 2005, 23, 7105-7113.	1.6	239
329	Antivascular Therapy for Orthotopic Human Ovarian Carcinoma through Blockade of the Vascular Endothelial Growth Factor and Epidermal Growth Factor Receptors. Clinical Cancer Research, 2005, 11, 4923-4933.	7.0	76
330	Therapeutic EphA2 Gene Targeting In vivo Using Neutral Liposomal Small Interfering RNA Delivery. Cancer Research, 2005, 65, 6910-6918.	0.9	632
331	Sequential Intraperitoneal Topotecan and Oral Etoposide Chemotherapy in Recurrent Platinum-Resistant Ovarian Carcinoma. Clinical Cancer Research, 2004, 10, 6080-6085.	7.0	21
332	Functional role of matrix metalloproteinases in ovarian tumor cell plasticity. American Journal of Obstetrics and Gynecology, 2004, 190, 899-909.	1.3	96
333	Biological Significance of Focal Adhesion Kinase in Ovarian Cancer. American Journal of Pathology, 2004, 165, 1087-1095.	3.8	232
334	The complexity of tumor vascularity. Cancer Biology and Therapy, 2003, 2, 257-8.	3.4	3
335	p53 Null Mutations are Associated with a Telomerase Negative Phenotype in Ovarian Carcinoma. Cancer Biology and Therapy, 2002, 1, 511-517.	3.4	14
336	The Clinical Significance of Tumor Cell-Lined Vasculature in Ovarian Carcinoma: Implications for Anti-Vasculogenic Therapy. Cancer Biology and Therapy, 2002, 1, 661-664.	3.4	89
337	Vascular endothelial growth factor and social support in patients with ovarian carcinoma. Cancer, 2002, 95, 808-815.	4.1	143